在欧盟建立药品单一市场:代价是什么?
Tineke Kleinhout-Vliek1, Susi Geiger1, Rob Hagendijk2
1College of Business, https://ror.org/05m7pjf47University College Dublin, Belfield, Dublin 4, Ireland.
Health economics, policy, and law
|October 27, 2025
概括
欧洲联盟 欧洲联盟
科学领域:
- 卫生政策 卫生政策
- 药品监管法规 药品监管法规 药品监管法规
- 市场经济学是市场经济学.
背景情况:
- 欧盟 (EU) 正在改革制药法规,以创建药品单一市场.
- 这些改革是更广泛的"欧洲卫生联盟"倡议的一部分.
- 当前的制药法规会影响市场动态和获得治疗的机会.
研究的目的:
- 在欧盟拟议的改革中分析制药法规与市场原则之间的相互作用.
- 调查欧盟内单一药品市场的实际影响.
- 评估改革如何平衡公平准入与市场竞争和定价.
主要方法:
- 对拟议的欧盟药品法规进行定性分析.
- 审查政策文件和改革建议.
- 检查了构想中的药品单一市场背后的经济原则.
主要成果:
- 改革的目标是公平地获得创新药物,但将其与监管排他性联系在一起,可能限制价格竞争.
- 药品定价的目的是保持很大程度上不透明,并由国家决定,而不是由欧盟一级的公开竞争驱动.
- 拟议的药品单一市场可能在没有直接价格引用或开放市场交易的情况下运作.
结论:
- 欧盟的药品单一市场可能无法实现预期的完全价格透明度或竞争.
- 监管排他性,虽然确保了访问,但可能会阻碍价格竞争.
- 这些改革并没有完全解决市场在没有直接价格参考的情况下运行的影响.
更多相关视频
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
230
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
230
Drug Control Governance: Regulatory Bodies and Their Impact
489
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
489
Biopharmaceutical Factors Influencing Drug Product Design: Overview
232
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
232
Bioequivalence: Overview
1.8K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.8K
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
148
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
148
Clinically Relevant Drug Product Specifications: Methods of Establishment
201
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
201


![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)